§ 01 Overview
Overview
ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome.
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
§ 02 Mechanism
Mechanism of action
Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- 01Microtubule stabilization
- 02Tau reduction in preclinical models
- 03Orphan designation for ADNP syndrome
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 5 – 30 mg per dose (trial)
- Route
- Intranasal
- Frequency
- Daily
- Cycle
- Trial-dependent
§ 04 Evidence
Evidence & research
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
FDA Status
Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Horse Racing Tips: Betfred's NAP of the Day for Tuesday 8 September 2026 - Betfred Insights
Horse Racing Tips: Betfred's NAP of the Day for Tuesday 8 September 2026 Betfred Insights
Mom's Clever Hack Saves Sleepy Senior Chihuahua From An Interrupted Nap - Yahoo
Mom's Clever Hack Saves Sleepy Senior Chihuahua From An Interrupted Nap Yahoo
Horse Racing Tips: Timeform’s Monday shots at Windsor - Paddy Power News
Horse Racing Tips: Timeform’s Monday shots at Windsor Paddy Power News
Tired behind the wheel? Have a double caffeine nap! - Central Bylines
Tired behind the wheel? Have a double caffeine nap! Central Bylines
'She can grab a first win off a very fair mark' - Templegate's NAP - The Irish Sun
'She can grab a first win off a very fair mark' - Templegate's NAP The Irish Sun
🎥Car burglary suspect arrested taking a nap on someone's porch - salinapost.com
🎥Car burglary suspect arrested taking a nap on someone's porch salinapost.com
Sleep Deprived? Why 20 Minutes of Exercise Competes with a 90-Minute Nap - Yahoo Health
Sleep Deprived? Why 20 Minutes of Exercise Competes with a 90-Minute Nap Yahoo Health
NAP of the Day: Raaheeb to prove a class act in Windsor feature - Betfred Insights
NAP of the Day: Raaheeb to prove a class act in Windsor feature Betfred Insights
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nasal irritation
- 02Headache
Contraindications
None specified.
§ 10 Questions
Davunetide (NAP) FAQ
- What is Davunetide (NAP)?
- ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome. Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- What is Davunetide (NAP) used for?
- Reported uses include microtubule stabilization, tau reduction in preclinical models, and orphan designation for adnp syndrome. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Davunetide (NAP) dosed?
- Commonly referenced dosing is 5 – 30 mg per dose (trial), typically daily, administered Intranasal. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Davunetide (NAP)?
- Commonly reported side effects include nasal irritation and headache. This list is not exhaustive.
- Is Davunetide (NAP) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome..
§ 11 References
Selected references
- 01
Boxer — PSP Phase 2/3
PMID: 24873720 (NCT01110720)
- 02
Gozes Transl Psychiatry 2023
PMID: 37845203